symptom management

Background: Sleep disturbance in persons with multiple sclerosis (pwMS) is associated with fatigue, depression, future cognitive decline, and worse quality …

Background: Nabiximols is a complex botanical mixture containing delta-9-tetrahydrocannibinol (THC), cannabidiol (CBD), other plant-derived cannabinoids, and non-cannabinoid constituents. It reduced …

Background: The North American Research Committee on Multiple Sclerosis (NARCOMS) registry is a voluntary, self-report registry for people with MS …

Background: Recent data have shown that PwMS may use cannabis to treat their complex symptoms, most frequently spasticity, pain, and …

Background: Depression is the most common symptom in Multiple Sclerosis (MS) patients with reported lifetime prevalence of 25-50%. Undetected and …

Background: Arbaclofen, the active R-enantiomer of baclofen, a racemic g-aminobutyric acid-B (GABAB) receptor agonist, has been a mainstay of treatment …

Background: Despite pharmacologic therapy, people with multiple sclerosis (MS) often experience spasticity, which can worsen with longer disease duration and …

Background: Individuals with Multiple Sclerosis (iMS) have increased postural sway and are at higher risk for falls. Some iMS describe …

Background: Arbaclofen is the active R-enantiomer of racemic baclofen. Arbaclofen extended-release (ER) tablets have demonstrated efficacy and safety in two …

Background: Fatigue is a common symptom in patients with Multiple Sclerosis (MS). Payor databases represent an important source of real …

Background: Evidence suggests that people with multiple sclerosis and spasticity (pwMSS) experience multiple concurrent symptoms that negatively impact daily functioning …